GLSI

GLSI

USD

Greenwich LifeSciences Inc. Common Stock

$9.630-0.015 (-0.156%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$9.645

Haut

$9.915

Bas

$9.600

Volume

0.02M

Fondamentaux de l'Entreprise

Capitalisation Boursière

128.7M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.08M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $8.06Actuel $9.630Haut $18.75

Actualités Connexes

GlobeNewswire

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Voir plus
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
GlobeNewswire

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Voir plus
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Voir plus
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
GlobeNewswire

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Voir plus
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.